Outcomes of an integrated care pathway for concurrent major depressive and alcohol use disorders: a multisite prospective cohort study

BMC Psychiatry

Andriy V. Samokhvalov¹  Bernard Le Foll¹  Jürgen Rehm¹  Saima Awan¹  Tony P. George¹  Peter Voore¹  Charlotte Probst² 

[1] Addictions Division, Centre for Addiction and Mental Health (CAMH);Institute for Mental Health Policy Research, CAMH;

关键词: Concurrent disorders;    Alcohol use disorder;    Major depressive disorder;    Care pathway;    Pharmacotherapy;    Psychotherapy;   

DOI  :  10.1186/s12888-018-1770-3

来源: DOAJ

【 摘 要 】

Abstract Background In 2013, an Integrated Care Pathway (ICP) for concurrent Major Depressive (MDD) and Alcohol Use (AUD) Disorders was developed at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada. The ICP was further implemented at 8 other clinical sites across Ontario (the DA VINCI Project) in 2015–2017. The goal of this study was to systematically describe and analyze the main clinical outcomes of the project. Methods Data on a non-randomized cohort of patients receiving ICP-based treatment were collected prospectively at nine clinical sites in a variety of clinical settings. Statistical methods: descriptive statistics, t-test, chi-square, ANOVA, generalized linear models. Results Two hundred forty-six patients were enrolled, 58.8% males, mean age was 45.6 years, 170 patients received treatment at academic health centres (AHC), 49 – at community hospitals (CH) and 27 – in family health teams (FHT). There were no major differences in anamnestic parameters and depression severity between the three settings, but there were differences in baseline drinking patterns between subgroups (F = 4.271, df = 2, p = 0.015). Overall completion rate was 70.7% with no significant variation between settings (χ2 = 3.35, df = 2, p = 0.19). Treatment duration in AHC was the longest, and completion rates were the highest. There was a statistically significant and clinically meaningful reduction in the number of drinking days per week (1.81, t = 8.78, p < 0.001). The cohort overall demonstrated significant and meaningful reduction in severity of cravings (Penn Alcohol Craving Scale: 4.42, t = 8.63, p < 0.001) and depressive symptoms (Quick Inventory of Depressive Symptomatology: 4.25, t = 11.26, p < 0.001). While some of the baseline patient characteristics and treatment parameters varied between the settings, the variation in clinical outcomes was mostly insignificant, though clinical improvement was more pronounced in academic setting and with individual therapy. Conclusions The study demonstrated that ICP is a feasible and effective treatment for concurrent AUD and MDD that delivers meaningful clinical improvement in a variety of settings. A randomized controlled study is needed to properly compare the treatment outcomes between ICP model and treatment as usual and to further explore the role of various factors on treatment outcomes.

【 授权许可】

Unknown